Histology
Squamous Cell Carcinoma
CI-CAN-00001550SCCExplore in graph →
977 active trials9 approved drugs78 evidence items
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00001550SCCExplore in graph →
Clinical trials
2,930 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (401)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04050436 | Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer(CERPASS) | active not recruiting | Phase 2 | 231 | Replimune, Inc.INDUSTRY | 10 | Jan 27, 2025 | clinicaltrials |
| NCT05202860 | Impact of Human Papillomavirus (HPV) Vaccination on Burden of Disease in Patients with Actinic Keratosis(VAXAK) | active not recruiting | Phase 2 | 70 | Merete HaedersdalOTHER | 1 | Jan 22, 2025 |
| clinicaltrials |
| NCT06489197 | AK112 Combined With Chemotherapy as the First-line Treatment in Advanced Esophageal Squamous Cell Carcinoma Patients | recruiting | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jan 22, 2025 | clinicaltrials |
| NCT06782555 | A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab | recruiting | Phase 1 / Phase 2 | 71 | ImmunoGenesisINDUSTRY | 1 | Jan 21, 2025 | clinicaltrials |
| NCT06087614 | Dose Escalation Using Hypoxia-adjusted Radiotherapy(DE-HyART) | recruiting | Phase 2 | 124 | Rajiv Gandhi Cancer Institute & Research Center, IndiaOTHER | 1 | Jan 17, 2025 | clinicaltrials |
| NCT03715946 | Adjuvant De-Escalated Radiation + Adjuvant Nivolumab for Intermediate-High Risk P16+ Oropharynx Cancer | completed | Phase 2 | 40 | Robert L. Ferris, MD, PhDOTHER | 1 | Jan 13, 2025 | clinicaltrials |
| NCT04649476 | Neoadjuvant PD-1 Blockade in Resectable Oral Squamous Cell Carcinoma(NEOPBOSCC) | completed | Phase 2 | 68 | Hospital of Stomatology, Wuhan UniversityOTHER | 1 | Jan 10, 2025 | clinicaltrials |
| NCT06422403 | A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers(VALUE-CHECK) | recruiting | Phase 2 | 360 | National University Hospital, SingaporeOTHER | 1 | Jan 10, 2025 | clinicaltrials |
| NCT03719924 | Nal-iri/lv5-fu Versus Paclitaxel as Second Line Therapy in Patients With Metastatic Oesophageal Squamous Cell Carcinoma(OESIRI) | completed | Phase 2 | 106 | Federation Francophone de Cancerologie DigestiveOTHER | 1 | Jan 8, 2025 | clinicaltrials |
| NCT04815720 | Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck(KEYNOTE-B84) | completed | Phase 1 / Phase 2 | 49 | Vaccinex Inc.INDUSTRY | 1 | Jan 8, 2025 | clinicaltrials |
| NCT02281955 | De-intensification of Radiation and Chemotherapy for Low-Risk HPV-related Oropharyngeal SCC: Follow-up Study | completed | Phase 2 | 115 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jan 7, 2025 | clinicaltrials |
| NCT06759155 | Phase II Clinical Trial of De-Intensified Therapy in Human Papilloma Virus (HPV) Associated Oropharyngeal Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 20 | University of Vermont Medical CenterOTHER | 0 | Jan 6, 2025 | clinicaltrials |
| NCT05007613 | Second-line Cabozantinib and Atezolizumab in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma | completed | Phase 2 | 24 | National Taiwan University HospitalOTHER | 1 | Jan 1, 2025 | clinicaltrials |
| NCT05214222 | Penpulimab Plus Chemotherapy With/Without Anlotinib for Patients With Advanced Esophageal Squamous Cell Carcinoma(ANSWER) | recruiting | Phase 2 | 100 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Dec 30, 2024 | clinicaltrials |
| NCT02573493 | Nab-Paclitaxel and Cisplatin or Nab-paclitaxel as Induction Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC)(APA) | completed | Phase 2 | 96 | Washington University School of MedicineOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT04807777 | Study of Ruxolitinib in Solid Organ Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma | terminated | Phase 2 | 3 | Columbia UniversityOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT03997968 | A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 169 | Cyteir Therapeutics, Inc.INDUSTRY | 1 | Dec 24, 2024 | clinicaltrials |
| NCT06746961 | Efficacy and Safety of QL1706 Plus Lenvatinib As 2nd Line Theapy in Patients with Metastatic Esophageal Carcinoma After Disease Progression on ICIs Therapy | not yet recruiting | Phase 1 / Phase 2 | 49 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 0 | Dec 24, 2024 | clinicaltrials |
| NCT03946358 | Combination of UCPVax Vaccine and Atezolizumab for the Treatment of Human Papillomavirus Positive Cancers (VolATIL)(VolATIL) | completed | Phase 2 | 47 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Dec 20, 2024 | clinicaltrials |
| NCT04719988 | Anti-PD-1 and mDCF Followed by Chemoradiotherapy in Patients With Stage III Squamous Cell Anal Carcinoma.(INTERACT-ION) | active not recruiting | Phase 2 | 55 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Dec 20, 2024 | clinicaltrials |
| NCT05877430 | Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer | recruiting | Phase 1 / Phase 2 | 160 | CJ Bioscience, Inc.INDUSTRY | 2 | Dec 20, 2024 | clinicaltrials |
| NCT06728618 | Preoperative Tislelizumab -Cetuximab - Chemotherapy Followed by Salvage Surgery and Adjuvant Tislelizumab -Cetuximab for Resectable, Locally Recurrent Oral and Oropharyngeal Squamous Cell Carcinoma(OSCC) | not yet recruiting | Phase 2 | 28 | Shanghai Zhongshan HospitalOTHER | 1 | Dec 11, 2024 | clinicaltrials |
| NCT04212598 | The Value of Sintilimab Consolidation Therapy After Definitive Concurrent Chemoradiotherapy for Locally Advanced Thoracic Esophageal Cancer | completed | Phase 2 | 40 | Wuhan UniversityOTHER | 1 | Dec 10, 2024 | clinicaltrials |
| NCT06725498 | Intra-arterial Chemotherapy Combined with Radiotherapy and Immunotherapy for HNSCC | recruiting | Phase 2 | 50 | Beijing Tongren HospitalOTHER | 1 | Dec 10, 2024 | clinicaltrials |
| NCT04843098 | Study of TL117 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | active not recruiting | Phase 1 / Phase 2 | 108 | Suzhou Junde Biotechnology Co., LtdINDUSTRY | 1 | Dec 9, 2024 | clinicaltrials |
| NCT06719479 | A Clinical Trial to Evaluate Effect of IAE0972 Combined with Chemotherapy for R/M HNSCC or NPC(Note: It is Currently Phase II.). | not yet recruiting | Phase 2 / Phase 3 | 60 | SUNHO（China）BioPharmaceutical CO., Ltd.INDUSTRY | 0 | Dec 5, 2024 | clinicaltrials |
| NCT05060471 | PD-1 Blockade Combined With Chemotherapy Followed by Concurrent Immunoradiotherapy for Locally Advanced SCCA Patients | completed | Phase 2 | 25 | Sun Yat-sen UniversityOTHER | 1 | Dec 3, 2024 | clinicaltrials |
| NCT06603402 | Low-Dose Involved-Field Radiotherapy Plus Immunochemotherapy for ESCC | recruiting | Phase 2 | 41 | Sichuan UniversityOTHER | 1 | Dec 3, 2024 | clinicaltrials |
| NCT06714266 | Trilaciclib in Preventing Hematopoietic Suppression in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 30 | Shandong Cancer Hospital and InstituteOTHER | 0 | Dec 3, 2024 | clinicaltrials |
| NCT06444009 | A Phase II Study of Neoadjuvant Immunotherapy in Combination With Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma | recruiting | Phase 2 | 90 | Lei LiuOTHER | 1 | Dec 2, 2024 | clinicaltrials |
| NCT06709417 | A Phase II Clinical Study of Sintilimab Combined with Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC) (NICE-CS) | recruiting | Phase 2 | 52 | Shanghai Chest HospitalOTHER | 1 | Nov 29, 2024 | clinicaltrials |
| NCT02538510 | Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery | completed | Phase 1 / Phase 2 | 50 | University of WashingtonOTHER | 1 | Nov 26, 2024 | clinicaltrials |
| NCT02647125 | A Study of Comparing Huachansu Plus Thoracic RT Versus RT Alone For ESCC | completed | Phase 2 | 126 | Fudan UniversityOTHER | 1 | Nov 26, 2024 | clinicaltrials |
| NCT06703047 | Tislelizumab Combined with Chemotherapy and All Trans Retinoic Acid for Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 180 | Fudan UniversityOTHER | 0 | Nov 25, 2024 | clinicaltrials |
| NCT03878979 | Preoperative Immune Checkpoint Inhibitor for Patients With Primary Untreated or Recurrent/Metastatic SCCHN | completed | Phase 2 | 26 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Nov 21, 2024 | clinicaltrials |
| NCT06699498 | Neoadjuvant Therapy of Targeted Immunotherapy Combined With Chemotherapy for Locally Advanced HNSCC | not yet recruiting | Phase 2 | 45 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Nov 21, 2024 | clinicaltrials |
| NCT06694350 | Pembrolizumab in Combination with Flutamide Treatment for Recurrence / Metastasis HNSCC | not yet recruiting | Phase 2 | 54 | Zhejiang Provincial People's HospitalOTHER | 0 | Nov 19, 2024 | clinicaltrials |
| NCT05520619 | Combination of Tislelizumab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-002)(EC-CRT-002) | active not recruiting | Phase 2 | 114 | Sun Yat-sen UniversityOTHER | 1 | Nov 18, 2024 | clinicaltrials |
| NCT02844075 | Preoperative Chemoradiotherapy and MK-3475 for Esophageal Squamous Cell Carcinoma (ACTS-29) | completed | Phase 2 | 28 | Yonsei UniversityOTHER | 1 | Nov 15, 2024 | clinicaltrials |
| NCT04787042 | Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 | recruiting | Phase 1 / Phase 2 | 316 | Simcha IL-18, Inc.INDUSTRY | 1 | Nov 15, 2024 | clinicaltrials |
| NCT06691503 | A Clinical Trial of Esophagectomy for Esophageal Carcinoma | completed | Phase 2 | 35 | Sun Yat-sen UniversityOTHER | 1 | Nov 15, 2024 | clinicaltrials |
| NCT03769467 | Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC) | terminated | Phase 1 / Phase 2 | 12 | Atara BiotherapeuticsINDUSTRY | 1 | Nov 14, 2024 | clinicaltrials |
| NCT01530997 | De-intensification of Radiation & Chemotherapy in Low-Risk Human Papillomavirus-related Oropharyngeal Squamous Cell Ca | completed | Phase 2 | 45 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Nov 13, 2024 | clinicaltrials |
| NCT03813836 | Phase II Trial of Pembrolizumab in Recurrent or Metastatic HNSCC(POPPY) | active not recruiting | Phase 2 | 63 | University College, LondonOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT06684600 | Study of Dalpiciclib Isethionate Plus Pyrotinib Maleate in the Treatment of Advanced Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 35 | Peking UniversityOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT04452032 | Prospective Pilot Study Evaluating Dental Side Effects of Radiotherapy on Subjects Treated for Head and Neck Cancer(StomRay) | active not recruiting | Phase 2 | 40 | Jules Bordet InstituteOTHER | 1 | Nov 8, 2024 | clinicaltrials |
| NCT03985046 | Sintilimab Plus Chemotherapy Followed by dCRT in Locally Advanced ESCC | completed | Phase 2 | 75 | Fudan UniversityOTHER | 1 | Nov 7, 2024 | clinicaltrials |
| NCT04220775 | Bintrafusp Alfa and Stereotactic Body Radiation Therapy for the Treatment of Recurrent or Second Primary Head and Neck Squamous Cell Cancer | terminated | Phase 1 / Phase 2 | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 7, 2024 | clinicaltrials |
| NCT06675201 | Neoantigen Vaccines in Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 165 | Sichuan UniversityOTHER | 1 | Nov 5, 2024 | clinicaltrials |
| NCT03153982 | Ruxolitinib in Operable Head and Neck Cancer | terminated | Phase 2 | 16 | University of California, San FranciscoOTHER | 1 | Oct 30, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Jan 27, 2025source: clinicaltrials